Key result
The rate of optimal guideline-recommended prescription for STEMI patients decreased from 74.3% at hospital discharge to 49.1% at 1-year follow-up, primarily due to statin dose reduction and early P2Y12 inhibitor discontinuation.
Why the study?
Cardiology guidelines recommend specific secondary prevention drugs for STEMI patients, but whether prescriptions adhere to guidelines at discharge and 1 year required assessment.
Observational (n=361)
No
While guideline-directed medical therapy prescription rates are high at discharge for STEMI patients, adherence declines significantly by 1 year, particularly for statins and P2Y12 inhibitors, with women and comorbid patients at highest risk for suboptimal therapy.
No takes yet. Share an insight, caveat, or question.
Declining optimal GDMT prescriptions by 1 year post-STEMI, especially in women, signals need for sustained monitoring; leaves open efficacy of adherence-focused interventions.
Bruggmann et al. (2019) conducted an observational in ST-Segment Elevation Myocardial Infarction (STEMI) (n=361). Guideline-recommended secondary prevention medications was evaluated on Adequacy of prescription of recommended drugs at discharge and at 1 year. The rate of optimal guideline-recommended prescription for STEMI patients decreased from 74.3% at hospital discharge to 49.1% at 1-year follow-up, primarily due to statin dose reduction and early P2Y12 inhibitor discontinuation.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: